Oric Announces Amended and Restated 2022 Incentive Plan
Oric Pharmaceuticals filed an amendment to its 2022 equity incentive plan to further attract and retain key personnel, including grants that qualify as inducement grants under Nasdaq Listing Rule 5635. Analysts view this positively as an indication of continued leadership confidence and HR stability.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day